Japan-based Nxera Pharma, formerly known as Sosei Group or Sosei Heptares, has entered into an exclusive supply and distribution agreement with Handok Inc. to commercialise PIVLAZ (clazosentan sodium) 150 mg in South Korea.
Tokyo, Japan and Cambridge, UK, 1 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce the launch of its new company name, having received approval at the 34th Ordinary General Meeting of Shareholders held on 27 March 2024. The Company’s new website can be found at www.nxera.life
Tokyo, Japan and Cambridge, UK, 27 March 2024 “ Sosei Group Corporation (the Company; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the...
Boehringer Ingelheim has secured an opportunity to beef up its schizophrenia portfolio courtesy of a €25 million ($27.3 million) upfront deal with Sosei Heptares.
Tokyo, Japan, and Cambridge, UK, 18 October 2023 “ Sosei Group Corporation (œSosei Heptares or œthe Company; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused...
Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development
Tokyo, Japan and Cambridge, UK, 20 September 2023 “ Sosei Group Corporation (œthe Company; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on...
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10...
Tokyo, Japan and Cambridge, UK, 4 August 2023 “ Sosei Group Corporation (œthe Company; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Tokyo, Japan and Cambridge, UK, 11 July 2023 €“ Sosei Group Corporation (€œthe Company€; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June...